Naringenin 7-O-cetyl ether as inhibitor of HMG-CoA reductase and modulator of plasma and hepatic lipids in high cholesterol-fed rats

Numerous studies in vitro have shown a close relationship between the chemical structure and biologic activity of flavonoids, whereby their basic structure is modified to increase or decrease their biologic activity. The effects of naringenin (1) and its synthetic derivative, naringenin 7-O-cetyl ether (2), on the lipid profile, the cholesterol-regulating enzyme activity and the excretion of sterol were compared in rats fed a high-cholesterol (1% wt/wt) diet. Either 1 or 2 was supplemented with a high-cholesterol diet for 6 weeks at a dose of 0.073 mmol/100 g diet. The supplementation of 1 or 2 significantly lowered the levels (mean SE) of the plasma total cholesterol (4.93 +/- 0.19 and 4.75 +/- 0.16 mmol/L vs 5.87 +/- 0.36 mmol/L, p < 0.05) and hepatic triglyceride (0.12 +/- 0.01 and 0.11 +/- 0.01 mmol/g vs 0.18 +/- 0.01 mmol/g, p < 0.05) and cholesterol (0.23 +/- 0.01 and 0.21 +/- 0.01 mmol/g vs 0.31 +/- 0.01 mmol/g, p < 0.05) compared to those of the control. The compound 1 or 2 supplementation appeared to decrease the excretion of neutral sterols. The plasma HDL-cholesterol concentration and ratio of HDL to total cholesterol were significantly higher in 1 and 2 groups than in control group. Although the biological effect of 2 on inhibiting hepatic HMG-CoA reductase and ACAT activities was only significant compared to the control group, both compounds exhibited a significant hypocholesterolemic effect in rats fed a high-cholesterol diet. The results suggest that cholesterol biosynthesis and esterification were concomitantly reduced by 2, as indicated by the decreased HMG-CoA reductase and ACAT activities. (C) 2002 Elsevier Science Ltd. All rights reserved.